NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News $8.05 -0.19 (-2.31%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$7.65▼$8.2850-Day Range$5.86▼$10.8952-Week Range$3.46▼$11.15Volume1.07 million shsAverage Volume825,944 shsMarket Capitalization$407.41 millionP/E RatioN/ADividend YieldN/APrice Target$21.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Marinus Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside167.1% Upside$21.50 Price TargetShort InterestBearish7.49% of Shares Sold ShortDividend StrengthN/ASustainability-1.56Upright™ Environmental ScoreNews Sentiment0.59Based on 2 Articles This WeekInsider TradingSelling Shares$131,258 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.56) to ($2.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.43 out of 5 starsMedical Sector181st out of 970 stocksPharmaceutical Preparations Industry65th out of 450 stocks 4.4 Analyst's Opinion Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Marinus Pharmaceuticals has a forecasted upside of 167.1% from its current price of $8.05.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.49% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarinus Pharmaceuticals has received a 62.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Epilepsy medication (N03)", "Clinical research services for Epilepsy or seizures", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marinus Pharmaceuticals is -1.56. Previous Next 2.0 News and Social Media Coverage News SentimentMarinus Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Marinus Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows91 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 2,933% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $131,258.00 in company stock.Percentage Held by InsidersOnly 4.86% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions88.26% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($2.56) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -53.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -53.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Marinus Pharmaceuticals (NASDAQ:MRNS) StockMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More MRNS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRNS Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by Cantor FitzgeraldSeptember 22, 2023 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)September 30, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 22, 2023 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $21.00September 22, 2023 | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $15.50 at LADENBURG THALM/SH SHSeptember 21, 2023 | finance.yahoo.comMarinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare ConferenceSeptember 21, 2023 | americanbankingnews.comMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 21, 2023 | markets.businessinsider.comMarinus Pharmaceuticals: Promising Clinical and Financial Progress Leads to Buy RatingSeptember 30, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 20, 2023 | markets.businessinsider.comMarinus (MRNS) Receives a Buy from JMP SecuritiesSeptember 19, 2023 | finance.yahoo.comMarinus Pharmaceuticals extends cash runway, shares surge 16%September 19, 2023 | msn.comMarinus stock jumps 11% on financial, pipeline updatesSeptember 19, 2023 | finance.yahoo.comMarinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst EventSeptember 12, 2023 | finance.yahoo.comMarinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023August 17, 2023 | finance.yahoo.comMarinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023August 12, 2023 | msn.comLadenburg Thalmann Maintains Marinus Pharmaceuticals (MRNS) Buy RecommendationAugust 11, 2023 | msn.comRBC Capital Maintains Marinus Pharmaceuticals (MRNS) Outperform RecommendationAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Marinus (MRNS)August 11, 2023 | msn.comOppenheimer Downgrades Marinus Pharmaceuticals (MRNS)August 11, 2023 | msn.comBaird Maintains Marinus Pharmaceuticals (MRNS) Outperform RecommendationAugust 10, 2023 | finance.yahoo.comMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comMarinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue EstimatesAugust 1, 2023 | msn.comMarinus gets EU approval for anti-seizure treatment ZtalmyJuly 31, 2023 | finance.yahoo.comMarinus secures European Commission approval for Ztalmy, triggering milestone paymentJuly 31, 2023 | finance.yahoo.comMarinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency DisorderJuly 27, 2023 | finance.yahoo.comMarinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023July 25, 2023 | finance.yahoo.comMarinus Pharmaceuticals (NASDAQ:MRNS) shareholders have earned a 71% return over the last yearSee More Headlines Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MRNS Company Calendar Last Earnings8/10/2023Today9/30/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees151Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.50 High Stock Price Forecast$32.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+167.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,820,000.00 Net Margins-113.01% Pretax Margin-99.51% Return on Equity-139.10% Return on Assets-52.35% Debt Debt-to-Equity Ratio1.75 Current Ratio7.60 Quick Ratio7.50 Sales & Book Value Annual Sales$25.48 million Price / Sales15.99 Cash FlowN/A Price / Cash FlowN/A Book Value$2.26 per share Price / Book3.56Miscellaneous Outstanding Shares50,610,000Free Float48,150,000Market Cap$407.41 million OptionableOptionable Beta1.35 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Scott N. Braunstein M.D. (Age 60)CEO, Pres & Chairman Comp: $919.29kMr. Steven E. Pfanstiel C.M.A. (Age 49)M.B.A., COO, CFO & Treasurer Comp: $580.35kDr. Joseph Hulihan M.D. (Age 67)Chief Medical Officer Comp: $639.51kDr. Alex Aimetti Ph.D.Chief Scientific OfficerMs. Sonya WeigleSr. VP of Investor Relations, HR & Corp. AffairsMs. Martha E. Manning Esq. (Age 68)J. D., Sr. VP, Gen. Counsel & Sec. Molly CameronDirector of Corp. Communications & Investor RelationsDr. Kimberly A. McCormick Pharm.D.PharmD, Chief Regulatory & Quality Assurance OfficerMr. Thomas J. LyonsChief Bus. OfficerMs. Christina Shafer (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsEdgewise TherapeuticsNASDAQ:EWTXLyell ImmunopharmaNASDAQ:LYELLiquidiaNASDAQ:LQDAORIC PharmaceuticalsNASDAQ:ORICNurix TherapeuticsNASDAQ:NRIXView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 16,574 shares on 8/21/2023Ownership: 0.033%Nuveen Asset Management LLCBought 139,477 shares on 8/16/2023Ownership: 0.276%Citadel Advisors LLCSold 1,500 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaBought 6,983 shares on 8/15/2023Ownership: 0.015%Walleye Trading LLCBought 4,100 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MRNS Stock - Frequently Asked Questions Should I buy or sell Marinus Pharmaceuticals stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRNS shares. View MRNS analyst ratings or view top-rated stocks. What is Marinus Pharmaceuticals' stock price forecast for 2023? 9 brokerages have issued 12 month target prices for Marinus Pharmaceuticals' stock. Their MRNS share price forecasts range from $9.00 to $32.00. On average, they predict the company's share price to reach $21.50 in the next year. This suggests a possible upside of 167.1% from the stock's current price. View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts. How have MRNS shares performed in 2023? Marinus Pharmaceuticals' stock was trading at $3.98 on January 1st, 2023. Since then, MRNS stock has increased by 102.3% and is now trading at $8.05. View the best growth stocks for 2023 here. When is Marinus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our MRNS earnings forecast. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.15. The biopharmaceutical company earned $6.08 million during the quarter, compared to the consensus estimate of $5.14 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 139.10% and a negative net margin of 113.01%. What ETFs hold Marinus Pharmaceuticals' stock? ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did Marinus Pharmaceuticals' stock split? Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO). What is Marinus Pharmaceuticals' stock symbol? Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS." How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Marinus Pharmaceuticals' stock price today? One share of MRNS stock can currently be purchased for approximately $8.05. How much money does Marinus Pharmaceuticals make? Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $407.41 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. How many employees does Marinus Pharmaceuticals have? The company employs 151 workers across the globe. How can I contact Marinus Pharmaceuticals? Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565. This page (NASDAQ:MRNS) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.